FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Clinical trials for FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA trials appear
Sign up with your email to follow new studies for FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo battles Tough-to-Treat ovarian cancer
Disease control OngoingThis study is for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to standard platinum-based chemotherapy. It aims to see if taking two oral drugs, cediranib and olaparib, together works better than taking either drug alone or…
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 04, 2026 05:20 UTC
-
Doctors test 'Trojan Horse' stem cells carrying Cancer-Killing virus
Disease control OngoingThis early-phase trial is testing a new treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after standard therapy. Researchers are using a patient's own fat-derived stem cells to carry a specially engineered measles virus directly to the cancer…
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 04, 2026 05:20 UTC
-
Pill vs. IV drip: major trial tests easier treatment for returning ovarian cancer
Disease control OngoingThis large, late-stage trial is testing whether taking pills (olaparib alone or with cediranib) works as well or better than standard intravenous chemotherapy for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned but still responds to platinum drugs. …
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Major trial tests new combo to fight back when ovarian cancer returns
Disease control OngoingThis large, late-stage trial is for people whose ovarian, fallopian tube, or primary peritoneal cancer has returned after initial successful treatment. It aims to find the best way to control the cancer by testing whether adding a drug called bevacizumab to standard chemotherapy,…
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for Tough-to-Treat ovarian cancers in early trial
Disease control OngoingThis early-stage study is testing a new two-drug combination for women with ovarian cancer that has returned after previous treatment. The main goal is to find the safest and most effective dose of an experimental pill (peposertib) when given with a standard chemotherapy drug. Re…
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC